Showing results (111-120 of 211) with videos related to

Sort By:
Pageof 22
European Journal of Haematology|October 30, 2023
Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational studyAlexandre Theocharides, Heinz Gisslinger, Valerio De Stefano, et al.
Frontiers in Oncology|February 18, 2022
Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study)Anna Sicuranza, Ilaria Ferrigno, Elisabetta Abruzzese, et al.
European Journal of Haematology|June 17, 2021
Nilotinib-induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 studyEster Pungolino, Mariella D'adda, Gabriella De Canal, et al.
Cancers|March 28, 2025
Bone Marrow CD34+/lin- Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) After 12 Months of Nilotinib Treatment Exhibit a Different Gene Expression Signature Compared to the Diagnosis and the Corresponding Cells from Healthy SubjectsAlessandra Trojani, Ester Pungolino, Barbara Di Camillo, et al.
Cancer Biomarkers : Section a of Disease Markers|October 18, 2017
Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatmentAlessandra Trojani, Ester Pungolino, Giuseppe Rossi, et al.
Leukemia|September 4, 2019
Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapyFabio Efficace, Fabio Stagno, Alessandra Iurlo, et al.
Cancers|April 3, 2021
Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded ImmunoliposomeMohammad Houshmand, Francesca Garello, Rachele Stefania, et al.
Leukemia Research|July 19, 2011
Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemiaLuigi Gugliotta, Alessia Tieghi, Giovanni Tortorella, et al.
Cancer|October 6, 2023
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemiaFabio Efficace, Francesco Cottone, Betina Yanez, et al.
Annals of Hematology|May 3, 2019
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practiceGiovanni Caocci, Olga Mulas, Elisabetta Abruzzese, et al.
Pageof 22